title: Massive pulmonary embolism: triple-armed therapy.
abstract: Many patients who suffer a massive pulmonary embolus die despite emergent therapy. In these desperately ill patients an aggressive, combined method of management was initiated to improve their chances and quality of survival. During a 5-year period 10 patients were treated with (1) low-dose topical, intrapulmonary thrombolytic therapy to dissolve thrombus, (streptokinase or urokinase); (2) anticoagulation to prevent thrombus propagation (heparin); and (3) the simultaneous insertion of a Greenfield filter to prevent the early, recurrent, and therefore potentially fatal pulmonary embolus--"triple-armed therapy." Thrombolytic therapy was administered through a Swan-Ganz catheter wedged against the pulmonary embolus. During the same interval 10 other patients also sustained massive pulmonary emboli but were treated only with systemic heparin. Serial pulmonary arteriography was performed daily. The patients treated by triple-armed therapy responded favorably with a rapid (less than 6 hours), significant improvement in PaO2, pulmonary artery pressure, cardiac output, pulmonary vascular resistance, and blood pressure, compared with patients treated with continuous heparin alone. Nine patients in the triple-armed therapy group survived whereas only six in the heparin group survived. Two additional patients were treated by triple-armed therapy and had thrombolysis with triple-armed therapy with tissue plasminogen activator; these patients demonstrated the most rapid improvement in cardiorespiratory dynamics and arteriographic clearance of emboli. This management protocol shows promise for patients who sustain a massive pulmonary embolus, because it reduces the morbidity associated with pulmonary embolectomy while avoiding the hazards associated with systemic thrombolytic therapy.
authors.affiliation: Department of Vascular Surgery, Georgia Baptist Medical Center, Medical College of Georgia, Atlanta.
authors.forename: D
authors.initials: D
authors.lastname: Rosenthal
authors.forename: R D
authors.initials: RD
authors.lastname: Evans
authors.forename: E
authors.initials: E
authors.lastname: Borrero
authors.forename: P A
authors.initials: PA
authors.lastname: Lamis
authors.forename: M D
authors.initials: MD
authors.lastname: Clark
authors.forename: W W
authors.initials: WW
authors.lastname: Daniel
mesh_terms: D000368:Aged; D001794:Blood Pressure; D002200:Capillary Resistance; D002302:Cardiac Output; D005260:Female; D005374:Filtration / Q000295:instrumentation*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000517:prevention & control; D012008:Recurrence; D013300:Streptokinase / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D014682:Vena Cava, Inferior
chemical_list: D006493:Heparin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator; D010100:Oxygen